In yesterday’s Wall Street session, Genelux Corporation (NASDAQ:GNLX) shares traded at $27.27, down -7.96% from the previous session.
1 analysts cover Genelux Corporation (NASDAQ:GNLX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $29.63, this indicates a potential downside of -66.25 percent. GNLX stock price is now 198.54% away from the 50-day moving average and 198.54% away from the 200-day moving average. The market capitalization of the company currently stands at $571.58M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target of $10, The Benchmark Company recently initiated with Speculative Buy rating for Genelux Corporation (NASDAQ: GNLX)..
In other news, Zhang Qian, Associate VP, Research bought 200 shares of the company’s stock on Jan 26. The stock was bought for $1,250 at an average price of $6.25. Upon completion of the transaction, the Associate VP, Research now directly owns 200 shares in the company, valued at $5454.0. A total of 18.41% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GNLX stock.
On Tuesday morning Genelux Corporation (NASDAQ: GNLX) stock kicked off with the opening price of $32.22. During the past 12 months, Genelux Corporation has had a low of $5.35 and a high of $36.50. The fifty day moving average price for GNLX is $9.13 and a two-hundred day moving average price translates $9.13 for the stock.
The latest earnings results from Genelux Corporation (NASDAQ: GNLX) was released for Sep, 2022. The net profit margin was -49.60% and return on equity was 15.50% for GNLX.
Genelux Corporation(GNLX) Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
